Correcting hyperprolactinemia may be an adjunct strategy for the treatment of obesity
Who Should NOT Consider Peptides Based on current evidence, I would advise against peptide use in the following individuals: Anyone with a current or recent cancer diagnosis Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal) Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.) Anyone with active autoimmune disease or severe inflammatory conditions Pregnant or breastfeeding women Anyone who has not established foundational health practices Competitive athletes (most peptides are banned substances) Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization If Considering Peptides: A Cautious Approach For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might considerwith significant caveats: Lower-Risk Starting Point Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health
AHFS Drug Information, 2012
UV radiation induces the synthesis of plasminogen activators by keratinocytes, which results in increased conversion of plasminogen to plasmin
Concentration = 10 mg 3 mL = 3.33 mg/mL (3,333 mcg/mL)
ECG, electrocardiogram
